AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca announced that its COPD drug met primary endpoints in two late-stage trials. The company previously forecast peak annual sales exceeding $5 billion for the treatment. Full trial data has been released supporting the drug's advancement toward regulatory review.

Next story